18F-氟脱氧葡萄糖PET/CT在小细胞肺癌中的应用:CONVERT随机对照试验分析
基于CONVERT 3期试验数据,540例局限期小细胞肺癌患者中,309例加用18F-FDG PET/CT分期者较231例常规影像分期者肿瘤体积更小、乳酸脱氢酶升高比例更低、化疗接受更多,但总生存和无进展生存无显著差异;常规影像组中骨显像与否无生存差异;PET/CT组正常组织放疗剂量更低,但常规影像组晚期食管炎(≥1级)发生率更高(19% vs 11%,p=0.012);作者认为因研究局限性,该分析不能支持使用或不使用18F-FDG PET/CT。
要点
- 加用18F-FDG PET/CT分期者肿瘤体积更小、乳酸脱氢酶升高比例更低、化疗接受更多。
- 两组总生存(HR=0.87,95%CI 0.70-1.08,p=0.192)和无进展生存(HR=0.87,95%CI 0.71-1.07,p=0.198)无显著差异。
- 常规影像组晚期食管炎(≥1级)发生率19% vs PET/CT组11%(p=0.012)。
核心结论
- CONVERT试验中,加用与不加用18F-FDG PET/CT分期者的生存结局无显著差异。
- 因研究局限性,该分析不能支持使用或不使用18F-FDG PET/CT。
研究设计与样本
- CONVERT为3期随机对照试验,将局限期小细胞肺癌患者随机分配至每日两次放疗(45 Gy/30次)或每日一次放疗(66 Gy/33次)联合化疗。
- 本分析为非计划分析,将540例患者分为常规影像分期组(n=231,胸腹部增强CT及脑影像,伴或不伴骨显像)和加用18F-FDG PET/CT分期组(n=309)。
主要发现
- 与常规影像组(n=231)相比,加用18F-FDG PET/CT组(n=309)肿瘤体积更小(p=0.003)、治疗前血清乳酸脱氢酶升高比例更低(p=0.035)、接受化疗更多(p=0.026)。
- 两组总生存无显著差异(HR=0.87,95%CI 0.70-1.08,p=0.192),无进展生存无显著差异(HR=0.87,95%CI 0.71-1.07,p=0.198)。
- 常规影像组中,伴或不伴骨显像分期的患者生存无差异。
- 两组放疗剂量无差异,但18F-FDG PET/CT分期组正常组织(肺、心脏、食管)放疗剂量更低。
- 常规影像组晚期食管炎(≥1级)发生率高于PET/CT组(19% vs 11%,p=0.012),急性和晚期放疗相关毒性发生率两组无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,因研究局限性,该分析不能支持使用或不使用18F-FDG PET/CT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We used phase-3 CONVERT trial data to investigate the impact of fludeoxyglucose F 18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) in SCLC. METHODS: CONVERT randomized patients with limited-stage SCLC to twice-daily (45 Gy in 30 fractions) or once-daily (66 Gy in 33 fractions) chemoradiotherapy. Patients were divided into two groups in this unplanned analysis: those staged with conventional imaging (contrast-enhanced thorax and abdomen CT and brain imaging with or without bone scintigraphy) and those staged with 18F-FDG PET/CT in addition. RESULTS: Data on a total of 540 patients were analyzed. Compared with patients who underwent conventional imaging (n = 231), patients also staged with 18F-FDG PET/CT (n = 309) had a smaller gross tumor volume (p = 0.003), were less likely to have an increased pretreatment serum lactate dehydrogenase level (p = 0.035), and received more chemotherapy (p = 0.026). There were no significant differences in overall (hazard ratio = 0.87, 95% confidence interval: 0.70-1.08, p = 0.192) and progression-free survival (hazard ratio = 0.87, 95% confidence interval: 0.71-1.07], p = 0.198) between patients staged with or without 18F-FDG PET/CT. In the conventional imaging group, we found no survival difference between patients staged with or without bone scintigraphy. Although there were no differences in delivered radiotherapy dose, 18F-FDG PET/CT-staged patients received lower normal tissue (lung, heart, and esophagus) radiation doses. Apart from a higher incidence of late esophagitis in patients staged with conventional imaging (for grade ≥1, 19% versus 11%; [p = 0.012]), the incidence of acute and late radiotherapy-related toxicities was not different between the two groups. CONCLUSION: In CONVERT, survival outcomes were not significantly different in patients staged with or without 18F-FDG PET/CT. However, this analysis cannot support the use or omission of 18F-FDG PET/CT owing to study limitations.
引用
- Manoharan P, Salem A, Mistry H, et al. 18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial. J Thorac Oncol. 2019. PMID: 31002954. doi:10.1016/j.jtho.2019.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。